Larson Financial Group LLC lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 40.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,108 shares of the company’s stock after selling 12,954 shares during the quarter. Larson Financial Group LLC’s holdings in Johnson & Johnson were worth $2,962,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Moneta Group Investment Advisors LLC lifted its stake in Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new stake in Johnson & Johnson in the fourth quarter worth $4,609,399,000. Morgan Stanley increased its position in Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the period. Nordwand Advisors LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth $785,273,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Johnson & Johnson by 15.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after purchasing an additional 3,849,148 shares during the period. 67.57% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of brokerages have recently commented on JNJ. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Atlantic Securities raised their target price on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Morgan Stanley restated an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a research report on Friday, July 21st. Finally, Raymond James raised their price objective on Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research report on Monday, July 24th. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Hold” and an average price target of $171.80.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The disclosure for this sale can be found here. Insiders have sold a total of 47,163 shares of company stock valued at $7,928,856 in the last 90 days. 0.20% of the stock is owned by corporate insiders.
Johnson & Johnson Stock Performance
Shares of NYSE JNJ opened at $173.15 on Wednesday. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The business’s 50 day moving average is $163.47 and its two-hundred day moving average is $161.02. The company has a market cap of $450.01 billion, a P/E ratio of 35.05, a P/E/G ratio of 2.90 and a beta of 0.54. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same quarter last year, the firm earned $2.59 EPS. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.75 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be paid a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.75%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 96.36%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- How to Use the MarketBeat Dividend Calculator
- 5 Best Fintech Stocks to Buy Now
- What is Forex: A Practical Guide on How to Trade Forex for Retail Investors
- UPS Slipping To More Attractive Levels On Weak OutlookÂ
- Investing in Blue-Chip Stocks
- More Good News Coming? GoodRx Spikes Ahead of Q2 Earnings
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
